has been shown to induce apoptosis in these cells. However, whether insulin-like growth factor-1 (IGF-1) inhibits IL-1β-induced apoptosis in the nucleus pulposus remains unclear. The purpose of this study was to investigate the effects of IGF-1 on IL-1β-induced apoptosis in the nucleus pulposus. Cells isolated from the nucleus pulposus were grown in culture to a monolayer. These cells were identified using immuno histochemistry for type II collagen and toluidine blue staining for glycosaminoglycans. Following exposure to IGF-1 or IL-1β, the cells were observed using light microscopy. Giemsa staining, TdT-mediated dUTP-biotin nick end-labeling (TUNEL) and flow cytometry (FCM) were used to detect the rate of early cell death, which served as an indicator of apoptosis. In the IL-1β group, a large number of these cells underwent apoptosis and demonstrated morphological changes associated with apoptosis. A small proportion of cells exposed to IGF-1 alone underwent apoptosis. No obvious signs of apoptosis were observed in the control group. TUNEL results revealed that the rate of apoptosis in the IGF-1 group was significantly reduced compared with that in the IL-1β group (P<0.01), confirmed using FCM. Compared with the control group, the apoptotic rate was also significantly increased in IL-1β-exposed cells (P<0.01). These findings strongly suggested that IGF-1 inhibits IL-1β-induced apoptosis in the nucleus pulposus.
Introduction
Intervertebral disc (IVD) degeneration is a common clinical problem that may result in low back pain and physical disability. Progressive loss of proteoglycans and disc dehydration, the major pathological characteristics of disc degeneration, may lead to alterations in disc structure and impaired disc function. The outer third of the IVD consists of the annulus fibrosus and nucleus pulposus. The latter is rich in proteoglycans, which are necessary for the normal function of the IVD. Recent findings have demonstrated that the number of nucleus pulposus cells is reduced and the composition of the extracellular matrix (ECM) associated with these cells is altered in degenerated discs (1) (2) (3) .
Interleukin (IL)-1, a proinflammatory cytokine present in the degenerating disc (4) (5) (6) , is thought to contribute significantly to the loss of ECM integrity and nucleus pulposus cells (3) . Only one cell line is present in the nucleus pulposus, and its constituents are responsible for secreting the content of the ECM. Therefore, the ability of IL-1β to reduce the number of cells in the nucleus pulposus and, thus, alter the characteristics of the ECM, may be important in the degeneration of the disc. Growth factors such as tumor growth factor (TGF)-β1 and insulin-like growth factor (IGF)-1 have been shown to stimulate the proliferation of nucleus pulposus cells in humans (7, 8) . Findings of previous studies suggested that growth factors also induce the regeneration of normal ECM in the IVD (9, 10) .
To determine whether there is a therapeutic role for growth factors in individuals with disc degeneration, we investigated the effects of IGF-1 on the IL-1β-induced loss of nucleus pulposus cells using light microscopy, Giemsa staining, TdT-mediated dUTP-biotin nick end-labeling (TUNEL) and flow cytometry (FCM).
Materials and methods
Cell culture. IVDs were obtained from lumbar spines of mature New Zealand white rabbits immediately postmortem. The nucleus pulposus was harvested from these specimens, washed with Hank's balanced salt solution (HBSS), and transported to the laboratory within 30 min of harvesting. 3 in size. Cells were isolated from the nucleus pulposus using sequential enzyme digestion with 0.25% trypsin for 30 min, washed with HBSS and incubated in 0.1% collagenase type II at 37˚C for 2-3 h. The cells were collected by filtering through a 200-mesh nylon cell strainer and subjected to centrifugation of 1,000 x g for 5 min. The cells were then washed twice with phosphate-buffered saline, resuspended and grown in medium containing Dulbecco's modified Eagle's medium with Ham's F-12 nutrient mixture (DMEM-F12) supplemented with 10% (vol/vol) fetal bovine serum (FBS) plus 1% penicillin and streptomycin. The culture medium was changed every 2-3 days. The phenotype of the nucleus pulposus cell was confirmed using positive immunostaining for type II collagen and toluidine blue staining of glycosaminoglycans. First-passage chondrocytes were used in our experiments.
Cells were grown in 80% confluency, first-passage chondrocytes were digested using trypsin and then transferred to 6-well plates to grow to a density of 1x10 5 /ml in DMEM-F12 supplemented with 10% (vol/vol) FBS. After 24 h of adherence, the medium was changed to DMEM-F12 without FBS, and the cells were cultured for another 24 h. At that time, the medium was removed, and the cells were grown in DMEM-F12 containing IL-1β (100 µg/l) with or without IGF-1 (500 µg/l) for 24 h. A subset of cells grown in DMEM-F12 without FBS for 24 h served as controls.
Animal care was carried out in accordance with the National Institute of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23; revised 1996) and was approved by the Bengbu Medical College Animal Care Committee of the Use of Laboratory Animals.
Giemsa staining. The cells were digested using trypsin and cultured in 6-well plates, each of which contained a 1x1-cm cover glass. The slides were removed 12 h later. The cells growing on each slide were fixed in methanol for 2 min. Giemsa staining solution was then applied for 10 min, and the cells were made transparent using xylene. The cells were then covered and observed using light microscopy.
TUNEL assay. The cells were again subjected to trypsinization and cultured in 6-well plates, each containing a 1x1-cm cover glass. The glass slides were removed 12 h later, and the cells growing on them were fixed in 4% paraformaldehyde for 60 min. Methanol containing 3% H 2 O 2 was then applied for 5 min to inactivate endogenous peroxidase. The cells were then exposed to 0.1% Triton X-100 at 4˚C for 2 min, incubated with 50 µl of the TUNEL reaction mixture (5 µl TdT-enzyme solution + 45 µl of nucleotide mixture solution) in the dark at 37˚C for 60 min, exposed to 3,3'-diaminobenzidine (DAB), and then counterstained with hematoxylin. The cells were then dehydrated using graded ethanol and covered with a xylene-based mounting medium. The percentage of TUNELpositive cells from the control, IL-1β and L-1β + IGF-1 groups were determined by counting the TUNEL-positive cells under 10 non-continuous low-power fields (magnification, x100).
Flow cytometry. Cells were cultured in DMEM-F12 containing IL-1β 100 µg/l with or without IGF-1 500 µg/l for 24 h. Cells cultured in DMEM-F12 without FBS for 24 h served as controls. The cells were then digested using trypsin, collected, washed in FCM buffer, and resuspended in FCM wash buffer. To detect cell apoptosis, the cells were incubated with 5 µl of Annexin V-FITC incubation reagent in the dark for 15 min at 4˚C, followed by incubation with propidium iodine (PI)-PE of 10 µl for 5 min at 4˚C. Samples were analyzed within 30 min using FCM.
Statistical analysis. Data were presented as the means ± SD (n=3). Groups of data were compared statistically using the Mann-Whitney U test. Values were considered statistically significant when P<0.05.
Results

Cultivation and identification of the nucleus pulposus cells.
Primary nucleus pulposus cells were obtained by sequential enzyme digestion and cultured in DMEM-F12 10% FBS (Fig. 1A) . Following culture for 7-10 days, the cells formed a complete monolayer (Fig. 1B) . To identify the nucleus pulposus phenotype cell, toluidine blue staining was used to identify glycosaminoglycans and immunostaining was used to detect type II collagen (Fig. 1C and D) . The results showed that these cells expressed both type II collagen and glycosaminoglycans, thus demonstrating the phenotype of nucleus pulposus cells.
IL-1β-induced apoptosis of nucleus pulposus cells.
The result obtained from Giemsa staining indicates that nuclear fragmentation occurred following culture of nucleus pulposus cells in the presence of 100 µg/l IL-1β (Fig. 2) , suggesting that IL-1β (Fig. 3A-C) .
IGF-1 reduced IL-1β-induced apoptosis of nucleus pulposus cells.
To determine whether IGF-1 affected IL-1β-induced apoptosis of nucleus pulposus cells, both 500 µg/l IGF-1 and 100 µg/l IL-1β were added into culture medium simultaneously. The result of TUNEL indicated that IL-1β-induced apoptosis was significantly suppressed (P<0.01) in the presence of IGF-1 (Fig. 3A and D) , suggesting that IGF-1 inhibits apoptosis of nucleus pulposus cells induced by IL-1β.
The results of TUNEL were confirmed by FCM. The percentage of nucleus pulposus cells with signs of early and late stages of apoptosis was significantly higher in the IL-1β group compared with the controls. However, the treatment of IGF-1 reduced IL-1β-induced apoptosis of nucleus pulposus cells (Fig. 4A-C, P<0 .01).
Discussion
Proinflammatory cytokines including IL-1β, IL-6, prostaglandin E2 and TNF are important in the mechanism underlying IVD (11-13). These cytokines are able to induce the production of factors associated with inflammation, pain and disc matrix catabolism in the nucleus pulposus (14) . IL-1β upregulates the expression of MMP-3 and MMP-9, which may contribute to the catabolism of the disc matrix (12), thereby playing an important role in the pathological degradation of the disc. Moreover, investigators found a simultaneous reduction in matrix synthesis factors (aggrecan, type II collagen, and Sox9) and an increase in inflammatory cytokine (IL-1β and TNF) levels during disc degeneration (15) . These observations indicate that proinflammatory cytokines stimulate the degradation of the ECM surrounding the nucleus pulposis, which may lead to disc degeneration.
The late stage of disc degeneration is characterized by a reduction in the number of nucleus pulposis cells, and IL-1β is thought to contribute significantly to this loss. Thus, IL-1β-induced nucleus pulposus cell apoptosis may also be involved in disc degeneration. Our findings have shown that IL-1β was able to induce apoptosis of nucleus pulposus cells. It has been proven that IGF-1 is efficient in stimulating the proliferation of human nucleus pulposus cells (9, 16) . Results of a recent study have indicated that exogenous and autocrine growth factors such as platelet-derived growth factor, basic fibroblast growth factor, and IGF-I stimulate the proliferation of human IVD through the MEK/ERK and PI-3K/Akt pathways (8) . Findings of an in vivo study indicated that age-related disc degeneration is associated with downregulation of the expression of IGF-1 (17), while findings of an in vitro study demonstrated that IGF-1-dependent proteoglycan synthesis decreased with age (9) . Taken together, these results suggest that IGF-1 likely contributes to the development of clinical interventions for disc degeneration. In the present study, the results from TUNEL and FCM indicated that the rate of apoptosis is particularly high in nucleus pulposus cells in the presence of IL-1β compared with the controls. However, when treated with IGF-1, the apoptosis of nucleus pulposus cells induced by IL-1β was reduced significantly, suggesting that IGF-1 reverses IL-1β-induced apoptosis of nucleus pulposus cells in vitro. The results from FCM also suggest that IL-1β induced both the early and late stages of apoptosis of nucleus pulposus cells and that the apoptosis was suppressed by IGF-1. These results were similar to those of a study suggesting that anabolic cytokines such as TGF and IGF-1 likely have a fundamental role in the prevention of degenerative disc disease (18, 19) , maintainance of ECM synthesis, and prevention of disc degeneration.
In conclusion, findings of this study have demonstrated that IGF-1 reverses IL-1β-induced apoptosis of nucleus pulposus cells. Thus, IGF-1 is a potentially appropriate target for the development of treatments for individuals with disc degenerative disease.
